See what’s clicking on FoxBusiness.com
The U.S. Food and Drug Administration (FDA) this week acknowledged a nationwide shortage of the attention-deficit hyperactivity disorder (ADHD) drug Adderall, confirming earlier warnings from manufacturers, pharmacists and patients.
The largest Adderall maker in the US, Teva Pharmaceuticals Industries, Ltd., said last month that a labor shortage earlier in the year caused production disruptions, but the company expects any retail bottlenecks to be resolved within weeks.
The FDA confirmed this week that there is a shortage of Adderall in the US (JB Reed/Bloomberg via Getty Images/Getty Images)
| ticker | security | Last | change | change % |
|---|---|---|---|---|
| TEWA | TEVA PHARMACEUTICAL INDUSTRIES LTD. | 7.95 | -0.26 | -3.17% |
But the shortage has since spread to other drug companies making generic versions of the treatment as desperate patients seek alternatives, and there are signs the situation may continue to deteriorate.
FDA APPROVES DUAL-VALUE COVID BOOSTER FOR YOUNG CHILDREN
The FDA said in its Wednesday press release that Teva is “experiencing ongoing intermittent delays in manufacturing,” indicating the disruptions from earlier in the year have not been resolved.
The Food and Drug Administration headquarters in White Oak, Maryland. (REUTERS/Andrew Kelly/File Photo/Reuters)
Last week, an FDA spokesman told FOX News Digital that the agency was in touch with makers of Adderall drugs and surveillance supplies but was on the verge of reporting a shortage.
WALMART, CVS REACH 147.5 MILLION USD OPIOID TREATMENT WITH WEST VIRGINIA
Experts say several factors are contributing to the shortages, including record-high prescriptions for the amphetamine blended salts following COVID-19 lockdowns, a surge in recreational use of the stimulant and limits imposed by the federal government that prohibit manufacturers from ramping up production when supplies run out become close.
New York Post columnist Karol Markowicz joined Kennedy to discuss her recent column about an increase in prescription drugs being given to children during the COVID-19 pandemic.
Despite pleas from patients who rely on the drug to get their fix but are unable to fill their prescriptions, federal agencies appear reluctant to allow drugmakers to ramp up production to meet demand .
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The U.S. Drug Enforcement Administration, which regulates production quotas for controlled substances, told the Wall Street Journal it has no plans to raise ADHD drug manufacturing limits next year. The agency cited concerns about abuse of the drugs by young adults.
